American type 2 diabetes care runs on a single assumption: the problem is fat tissue, so the fix is to shrink it. A Brazilian fish oil study in a rat strain that gets diabetic without ever getting fat just complicated that story. The glucose numbers moved. The T-cells moved more, and that is what I keep circling back to.

The paper is out in Nutrients (16:4106), from Tiago Bertola Lobato in Renata Gorjão and Rui Curi’s group at Cruzeiro do Sul University in São Paulo. The funders are FAPESP, CNPq, and CAPES, three Brazilian public science agencies. No industry money in the disclosure, and the authors declared no commercial or financial conflicts. That matters for a fish oil paper, because the field is awash in supplement-industry-adjacent trials and this one isn’t.

Start with the model, because it carries the whole story. The Goto-Kakizaki rat is a non-obese type 2 diabetic strain, bred over generations from glucose-intolerant Wistars, and it develops diabetes without ever getting fat.

That sounds like a niche detail until you remember how the metabolic conversation actually runs. Worldwide, somewhere in the range of 10 to 20 percent of type 2 diabetes patients are non-obese at diagnosis, and the share is meaningfully higher in Asian populations. Those people exist, they have insulin resistance, and the standard “lose weight first” pathway, now reaching for a $1,200-a-month GLP-1 agonist, has very little to say to them. A model that gets diabetic without obesity is one of the rare experimental settings where you can watch the inflammation story without the fat-tissue story drowning it out.

The fish oil itself was concentrated heavily toward EPA: 540 mg of eicosapentaenoic acid and 100 mg of docosahexaenoic acid per gram, a roughly 5.4 to 1 EPA:DHA ratio. That is not what an off-the-shelf softgel delivers; standard consumer formulations sit closer to 1 to 1 and at much lower per-capsule potency. The rats got 2 grams per kilogram of body weight, three times a week, by oral gavage, for eight weeks. Sample sizes were small but not absurd for this kind of work: 14 control Goto-Kakizaki rats versus 15 supplemented, with Wistars run alongside as the non-diabetic comparison.

The expected things happened. Glucose tolerance improved, insulin resistance dropped, lipids moved the friendlier way (total cholesterol, LDL, and triglycerides all down), and systemic inflammatory markers fell. If the paper had stopped there, it would be a fine but unremarkable confirmation of a story most people already half-believe.

It didn’t stop there. The team profiled lymphocytes from these animals and found a wholesale shift in the balance of T-cell subsets. Th1 cells dropped. Th17 cells, the same population that drives chronic inflammation in psoriasis and inflammatory bowel disease, dropped. Regulatory T-cells, the Tregs whose job is to keep the immune system from overreacting, rose. The immune cast pulled toward tolerance, and the metabolic numbers moved alongside that shift.

Wait, why would supplemented fatty acids rebalance your T-cell repertoire? Because the membranes of those cells, and the signaling lipids they release, are literally built from what’s in the diet. Swap the substrate, and the messengers change. The paper can’t prove the T-cell shift drove the glucose improvement (the two moved together, not one then the other), but the implication is hard to ignore: the chronic low-grade inflammation behind insulin resistance isn’t an abstraction. It runs through specific cell populations doing measurable damage to insulin signaling in tissue. If you can shift which cells are doing the inflaming, weight loss as the entry point starts to look less mandatory.

Cold water, because the discipline matters and this is a rat study. The dose, scaled by surface area the way pharmacologists do, lands somewhere around 320 mg per kilogram in a human, which is roughly 22 grams of this specific high-EPA formulation, three times a week, for an average adult. That is many multiples of what people actually take. The human evidence is, charitably, unsettled. ASCEND tested 1 gram per day of marine omega-3 in 15,480 adults who already had diabetes and found no significant reduction in serious vascular events. The VITAL ancillary in adults without diabetes at baseline likewise did not show that omega-3 prevented incident type 2 diabetes. The trials we have were dosed about an order of magnitude lower than this rat study and weren’t designed around the lean type 2 phenotype that the Goto-Kakizaki model actually represents. Read this paper as a mechanism signal, not a dosing instruction.

Now the market piece, and I want to be exact about it. Prescription omega-3 products do exist; Vascepa, the patented EPA ethyl ester, already sits in cardiologists’ tool drawers. But the commercial gravity that funds large multicenter trials sits with patent-protected molecules, not with high-dose generic nutrients aimed at a phenotype the bulk of US clinicians treat as a rounding error. That gap shows up in the trial pipeline. The interesting question this paper raises (is the inflammation route the actual lever in lean type 2?) is exactly the kind of question generic nutrients tend to leave unanswered, because nobody’s stock chart depends on the answer.

What I take from this, plainly. I’m not telling you to go take 22 grams of fish oil; I’m not even sure what dose the human version of this study would land on. What I am more convinced of than I was a week ago is that the inflammation-to-insulin-resistance axis is doing structural work in the lean type 2 phenotype, and that an EPA-weighted omega-3 is a defensible thing to put on the table with your doctor if you’re in that bucket. The T-cell piece is the part of this story I find hardest to dismiss, and the part I’ll be watching as the human trials catch up.

Sources

  1. Lobato TB et al., Nutrients 2024 – Omega-3 Fatty Acids Weaken Lymphocyte Inflammatory Features and Improve Glycemic Control in Nonobese Diabetic Goto-Kakizaki Rats (PMC11644024)
  2. ScienceDaily – Omega-3 fish oil shows promise against type 2 diabetes (2026)
  3. FAPESP – Consumption of omega-3 weakens insulin resistance in non-obese rats, study shows
  4. ASCEND trial – Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, NEJM 2018
  5. VITAL trial – Vitamin D and Omega-3 Trial, ClinicalTrials.gov NCT01633177